Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 13Lymphoma 8Lymphoma, Non-Hodgkin 7Recurrence 4Solid Tumor 3Melanoma 3Lymphoma, Large-Cell, Anaplastic 3Advanced Solid Tumors 3Solid Tumors 2Hodgkin Disease 2Hematologic Neoplasms 2Hematologic Diseases 2Carcinoma, Non-Small-Cell Lung 2Solid Tumours 1Solid Tumor, Adult 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma 1Malignancies Multiple 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Carcinoma 1Advanced Solid Tumours 1Advanced Solid Tumor 1Advanced Solid Neoplasm 1

Interventions

darolutamide 1Rifampin 1Itraconazole 1Hydroxychloroquine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Refractory or Relapsed Solid Tumors × Rifampin × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡